HF
UNCY icon

HRT Financial’s Unicycive Therapeutics UNCY Stock Holding History

HRT Financial’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41,492
Closed -$273K – 5390
2026
Q1 		$273K Buy
+41,492
New +$272K ﹤0.01% 2951
2025
Q2 		– Sell
-1,782
Closed -$10K – 3559
2025
Q1 		$10K Sell
1,782
-431
-19% -$2.63K ﹤0.01% 2354
2024
Q4 		$17K Buy
+2,213
New +$12.3K ﹤0.01% 2227

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

HRT Financial's UNCY Position: Q2 2026 in Review

HRT Financial sold out of Unicycive Therapeutics (UNCY) in Q2 2026, closing a stake of 41,492 shares — an estimated $273K sold.

HRT Financial first reported a position in UNCY in Q4 2024 and held it in 3 quarters. The position peaked at $273K in Q1 2026. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • HRT Financial reported no remaining Unicycive Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 41,492 Unicycive Therapeutics shares in Q2 2026, an estimated $273K.
  • HRT Financial first reported a position in Unicycive Therapeutics in Q4 2024 and held it in 3 quarters.
  • HRT Financial's Unicycive Therapeutics position peaked at $273K in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.